Europe's competition watchdog has slapped Israeli pharmaceutical giant Teva and its subsidiary Cephalon with more than €60 million (about $71 million) in fines for conspiring to keep a generic version of the narcolepsy drug Provigil off the market.
AbbVie Inc. on Monday partially beat a suit over an alleged kickback scheme to boost prescriptions of its blockbuster immunosuppressant drug Humira when an Illinois federal judge limited the case to only Florida-related allegations.
The Eleventh Circuit on Monday backed dismissal and sanctions in a retaliation and age discrimination suit against the medical device manufacturer Stryker Sales Corp., saying a former employee's false testimony and "bad faith" action justified the penalties.
A U.S. District Court judge in Delaware on Monday shot down Coherus BioSciences Inc.'s bid to shift legal fees to Amgen Inc. in its failed patent infringement suit against Coherus over a blockbuster anti-infection drug.
Moderna on Monday said it is filing an emergency approval request with the U.S. Food and Drug Administration, asking the regulator to sign off on its COVID-19 vaccine that the drugmaker claims is 100% effective at preventing severe cases and 94% effective at preventing infection.
Greenberg Traurig LLP has hired an attorney who worked for more than a decade with the federal agency that oversees Medicare and Medicaid to join the firm's health care and U.S. Food and Drug Administration practice.
Law360 congratulates the winners of its 2020 Practice Groups of the Year awards, which honor the law firms behind the litigation wins and major deals that resonated throughout the legal industry in the past year.
The eight law firms topping Law360's Firms of the Year managed to win 54 Practice Group of the Year awards among them, for guiding landmark deals, scoring victories in high-profile disputes and helping companies navigate uncharted legal seas made rough by the coronavirus pandemic.
Four subsidiaries of Chinese company BGI Group seeking to invalidate patents behind an American company's system for rapid DNA sequencing maintained in closing arguments at trial on Friday that the techniques at issue were obvious based on earlier lessons.
A Missouri federal judge on Wednesday cut a punitive damages award that a Missouri farm won against Monsanto and BASF in a bellwether trial over claims the weedkiller dicamba ruined the farm's peach trees from $250 million to $60 million, ruling that the case involved only economic damages as opposed to physical harm.
Zydus Pharmaceuticals punctuated the six-day trial in its bid to bring generic diabetes drugs to market by filing a 100-page, post-trial brief doubling down on its claim that Mitsubishi Tanabe Pharma Corp. is engaging in "gamesmanship" to extend the life of one of three patents Zydus is accused of infringing.
The European Commission on Wednesday adopted a plan to develop a regulatory framework by 2022 to increase access to cheap generic drugs by cracking down on anti-competitive behaviors by pharmaceutical companies across the European Union.
A New Jersey appellate panel said Wednesday there were serious problems with the way the state scored medical marijuana permit applications, sending the state's Department of Health back to reconsider applications submitted by rejected companies.
The Federal Circuit misapplied clear U.S. Supreme Court precedent when finding that administrative patent judges weren't constitutionally appointed, the government and medical tech company Smith & Nephew said Wednesday in their opening salvos for the closely watched Arthrex case.
SmileDirectClub has told the Ninth Circuit that a California federal court was wrong to find that what the company calls a harassment campaign by the state's dental board was instead a proper exercise of its regulatory authority.
The U.S. Government Accountability Office denied a bid protest from the global research firm Battelle Memorial Institute on Wednesday, the company's third such protest, because it found that the company's proposal had not been disparately evaluated by the Centers for Disease Control and Prevention.
Mass spectrometry company 908 Devices on Wednesday filed for an initial public offering guided by Goodwin Procter LLP that is preliminarily estimated to bring in about $75 million.
Ahead of the long weekend, when Americans are most known for gathering and traveling, Thanksgiving-minded governors laid down more restrictions as COVID-19 cases continued surging over the past week.
The U.S. Department of Justice on Wednesday announced that a North Carolina man and his sport supplement company pled guilty to a felony charge for illegally distributing steroids with the intent to defraud consumers and the U.S. Food and Drug Administration and agreed to forfeit $1.2 million.
Parents who bought infant fever medication made by Prestige Consumer Healthcare Inc. are suing the company in California federal court, alleging in a proposed class action that the drugs are the same dosage and formula as the medication labeled for children, but at nearly double the price.
An Illinois federal judge said on Monday that a cannabis telehealth service could not evict a medical marijuana business from its platform even if some of the company's practices were questionable, saying there was no material violation of the pair's agreement.
An organization representing top pharmaceutical research firms and two health care advocacy groups have sued the Trump administration in D.C. federal court to block a new federal policy allowing states, tribes, pharmacists and wholesalers to import certain prescription drugs from Canada without approval from drug manufacturers.
An Iowa federal jury has awarded $3.5 million over a hip implant patient's claims that her Biomet M2a Magnum metal hip shedded microscopic particles and caused her to need revision surgery.
Pointing to "overly aggressive" efforts by Gilead Sciences Inc. to shut down demands for records as part of stockholder investigations into potential company malfeasance over its AIDS drug, a Delaware vice chancellor has ordered the company to cooperate and authorized investors to seek shifting their legal fees to the company, saying Gilead's conduct "epitomizes a trend."
A Pennsylvania hospital system urged a federal judge to throw out parts of a discrimination lawsuit filed by a former employee who was fired after testing positive for marijuana, saying state courts have rejected the idea that medical pot use is protected.
The U.S. Department of Health and Human Services accused Gilead Sciences Inc. on Wednesday of infringing four agency patents covering the use of HIV treatment medication to prevent infection, escalating a fight that has been brewing for months.
The Biden administration is unlikely to successfully push sweeping and partisan health care legislation in the next two years, but it will be able to reverse a litany of Trump administration policies pertaining to the Affordable Care Act, reproductive health care and more, say Nick Manetto and Ilisa Halpern Paul at Faegre Drinker.
Attorneys can use a new predeposition meet-and-confer obligation for federal litigation — taking effect Tuesday — to better understand and narrow the topics of planned testimony, and more clearly outline the scope of any discovery disputes, says James Wagstaffe at Wagstaffe von Loewenfeldt Busch.
Congressional investigations in the health care, financial services, fossil fuel and technology sectors are likely to intensify next year amid a highly partisan environment, and companies that may be targets should get ready for testimony and document production well before an inquiry, say attorneys at Hogan Lovells.
Many organizations are making plans for executives to go into government jobs, or for government officials to join a private sector team, but they must understand the many ethics rules that can put a damper on just how valuable the former employee or new hire can be, say Scott Thomas and Jennifer Carrier at Blank Rome.
As New Jersey's ballot measure approving adult-use cannabis gives the state a strong head start in the race to legalization, neighboring states Pennsylvania, New York and Connecticut need to move quickly to follow suit or risk losing out on significant cannabis tax revenue, say attorneys at Saul Ewing.
Attorneys at Ropes & Gray explore four types of high-impact drug pricing initiatives at the state level — pricing transparency, pharmacy benefit manager controls, drug importation and value-based arrangements — examining how the current wave of reforms may affect drug companies' business operations.
Although some judges are apprehensive of a "turducken" analysis — a patent case stuffed inside a reverse-payment antitrust action — it is procedurally viable and may be a fair way to adjudicate the antitrust liability of generic companies settling Hatch-Waxman litigation, say attorneys at Katten.
When the Biden administration takes control of the U.S. Food and Drug Administration, companies can expect to see increased attention to the safety of medical devices, the rigor of audits and inspections, and the concerns of consumer advocacy groups, say attorneys at Covington.
As the pandemic brings a variety of legal stresses for businesses, lawyers must understand the emotional dynamic of a crisis and the particular energy it produces to effectively fulfill their role as advisers, say Meredith Parfet and Aaron Solomon at Ravenyard Group.
During the Trump administration, the U.S. Food and Drug Administration has tended to issue warning letters and other regulatory tools to secure voluntary corrective actions, but the Biden administration is likely to pursue more vigorous judicial enforcement, including through consent decrees and criminal referrals, say attorneys at Covington.
With the pandemic contributing to rising rates of opioid and substance use disorders, prosecutors should consider the regrettably underused Eliminating Kickbacks in Recovery Act as a tool for targeting and shutting down body brokers and others in the treatment industry that place profits above patients, say Michael Adelberg and Matthew Rubin at Faegre Drinker, and Melissa Garrido at Boston University.
Richard Finkelman and Yihua Astle at Berkeley Research Group discuss the ethical and bias concerns law firms must address when implementing artificial intelligence-powered applications for recruiting, conflict identification and client counseling.
Baca v. Johnson & Johnson, a recent pelvic mesh lawsuit brought in Arizona federal court, is a perfect example of how some product liability cases that might be accepted in a multidistrict litigation contain deficiencies that cannot withstand scrutiny when tried individually, says Rachel Weil at Reed Smith.
Three federal court decisions addressing the Public Readiness and Emergency Preparedness Act suggest that the law likely preempts state claims related to a COVID-19 vaccine, but is unlikely to cover the failure to administer the vaccine, says Nathan Adams at Holland & Knight.
Attorneys should consider the pros and cons of participating in virtual court proceedings from home versus their law firm offices, and whether they have the right audio, video and team communication tools for their particular setup, say attorneys at Arnold & Porter.